ERBB2 and cancer: This is slightly higher than the rate of all stage IV cancers in Ontario (< 5%) [19] and underscores the findings of a US study that hypothesized that an increasing incidence of stage IV tumors, despite increased screening, is likely due to the growing contribution of aggressive phenotypes like triple negative and HER2+ BC [20].